These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 6814244)

  • 21. Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator.
    Booth NA; Anderson JA; Bennett B
    J Clin Pathol; 1984 Jul; 37(7):772-7. PubMed ID: 6235248
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The influence of L-asparaginase therapy on the fibrinolytic system.
    Vellenga E; Kluft C; Mulder NH; Wijngaards G; Nieweg HO
    Br J Haematol; 1984 Jun; 57(2):247-54. PubMed ID: 6203549
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Contact (prekallikrein) and fibrinolytic (plasminogen/antiplasmin value) system in the physiopathology of vascular complications of diabetes].
    Janody D; Droulle C; Adjizian JC; Ostermann G; Poynard JP; Jeunehomme G; Leutenegger M; Potron G
    J Mal Vasc; 1982; 7(3):221-4. PubMed ID: 6815291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of the intron 22 inversion of the factor VIII gene and inhibitor development in Polish patients with severe hemophilia A.
    Sawecka J; Skulimowska J; Windyga J; Lopaciuk S; Kościelak J
    Arch Immunol Ther Exp (Warsz); 2005; 53(4):352-6. PubMed ID: 16088320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Fibrinolytic system in patients with myocardial infarction and other coronary disease risk factors].
    Moreno JA; Gálvez MM; Cornudella R; Angós JA; Romero MS; Gutiérrez M
    Sangre (Barc); 1994 Apr; 39(2):111-6. PubMed ID: 8059288
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in plasma haptoglobin and alpha-2-macroglobulin in hemophiliacs receiving factor replacement therapy.
    Shulman G; Ballard JO; Eyster ME
    Am J Hematol; 1985 Mar; 18(3):223-33. PubMed ID: 2579546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The blood coagulation system in progressive systemic scleroderma].
    Sica S; Paoletti S; Storti S; Pagano L; Marra R; Garcovich A
    Minerva Med; 1987 Dec; 78(24):1831-4. PubMed ID: 2448705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blood coagulation, fibrinolytic, and inhibitory proteins in end-stage renal disease: effect of hemodialysis.
    Vaziri ND; Gonzales EC; Wang J; Said S
    Am J Kidney Dis; 1994 Jun; 23(6):828-35. PubMed ID: 8203365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The fibrinolytic system in patients with congenital protein C deficiency.
    Conard J; Horellou MH; Teger-Nilsson AC; Bertina RM; Samama M
    Thromb Res; 1984 Nov; 36(4):363-7. PubMed ID: 6549234
    [No Abstract]   [Full Text] [Related]  

  • 30. Releasing the Brakes on the Fibrinolytic System in Pulmonary Emboli: Unique Effects of Plasminogen Activation and α2-Antiplasmin Inactivation.
    Singh S; Houng A; Reed GL
    Circulation; 2017 Mar; 135(11):1011-1020. PubMed ID: 28028005
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of kringles derived from human plasminogen on fibrinolysis in vitro.
    Sugiyama N; Iwamoto M; Abiko Y
    Thromb Res; 1987 Aug; 47(4):459-68. PubMed ID: 2821651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Paradoxical bleeding in intensively transfused hemophilics: alteration of platelet function.
    Hathaway WE; Mahasandana C; Clarke S; Humbert JR
    Transfusion; 1973; 13(1):6-12. PubMed ID: 4685225
    [No Abstract]   [Full Text] [Related]  

  • 33. Plasminogen, alpha(2)-antiplasmin and complexes of plasmin-alpha(2)-antiplasmin (PAP) in amniotic fluid and blood plasma of parturient women.
    Uszynski M; Klyszejko A; Zekanowska E
    Eur J Obstet Gynecol Reprod Biol; 2000 Dec; 93(2):167-71. PubMed ID: 11074138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular mechanism of fibrinolysis.
    Lijnen HR; Collen D
    Adv Exp Med Biol; 1984; 164():217-28. PubMed ID: 6421102
    [No Abstract]   [Full Text] [Related]  

  • 35. Increased blood viscosity and fibrinolytic inhibitor in type II hyperlipoproteinaemia.
    Lowe GD; McArdle BM; Stromberg P; Lorimer AR; Forbes CD; Prentice CR
    Lancet; 1982 Feb; 1(8270):472-5. PubMed ID: 6121140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors and inhibitors of blood coagulation and fibrinolysis in promyelocytic leukemia.
    Bratt G; Blombäck M; Lockner D
    Scand J Clin Lab Invest Suppl; 1985; 178():81-3. PubMed ID: 3937221
    [No Abstract]   [Full Text] [Related]  

  • 37. Changes in the coagulation and fibrinolytic systems during and after cardiopulmonary bypass surgery.
    Kongsgaard UE; Smith-Erichsen N; Geiran O; Bjørnskau L
    Thorac Cardiovasc Surg; 1989 Jun; 37(3):158-62. PubMed ID: 2527423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chromogenic peptide substrates. Their use for the assay of factors in the fibrinolytic and the plasma kallikrein-kinin systems.
    Friberger P
    Scand J Clin Lab Invest Suppl; 1982; 162():1-298. PubMed ID: 6221396
    [No Abstract]   [Full Text] [Related]  

  • 39. Plasminogen activators and antiplasmin activity in atopic dermatitis.
    Lotti T; Battini ML; Brunetti L; Fabbri P; Panconesi E
    Int J Dermatol; 1989 Sep; 28(7):457-9. PubMed ID: 2777445
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fibrinolysis in health and disease: abnormal levels of plasminogen activator, plasminogen activator inhibitor, and protein C in thrombotic thrombocytopenic purpura.
    Glas-Greenwalt P; Hall JM; Panke TW; Kant KS; Allen CM; Pollak VE
    J Lab Clin Med; 1986 Nov; 108(5):415-22. PubMed ID: 2430036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.